MedTrace Logo

Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer

NCT03322020 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-07-05

No results posted yet for this study

Summary

For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy and 21 Gy in 3 fractions, respectively. The investigators plan to evaluate the toxicity of two dose groups and decide the appropriate dose for Cyberknife boost. Also, PSA control will be evaluated.

Conditions

  • Neoplasm, Prostate

Interventions

RADIATION

Cyberknife boost 18 Gy

pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx

RADIATION

Cyberknife boost 21 Gy

pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Young Seok Kim, M.D., Ph.D. · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-21
Primary Completion
2018-06-30
Completion
2019-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322020 on ClinicalTrials.gov